Structure-based molecular design, synthesis, and in vivo anti-inflammatory activity of pyridazinone derivatives as nonclassic COX-2 inhibitors

Medicinal Chemistry Research

Volumn 19, Issue 7, 2010, Pages 629-642

  Abouzid, Khaled A M ^c   Khalil, Nadia A ^a   Ahmed, Eman M ^a   El Latif, Hekmat A Abd ^a   El Araby, Moustafa E ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b Helwan   (Egypt)

^c NONE

Author keywords

Anti inflammatory; Molecular design; Pyridazinone; Quinoxaline; Synthesis

Indexed keywords

2 (4 CHLOROPHENYL) 3 (6 OXO 1,6 DIHYDROPYRIDAZIN 3 YL) 1,2,3,4 TETRAHYDROQUINOXALINE; 2 (4 CHLOROPHENYL) 3 (6 OXO 1,6 DIHYDROPYRIDAZIN 3 YL)QUINOXALINE; 2 (4 METHOXYPHENYL) 3 (6 OXO 1,6 DIHYDROPYRIDAZIN 3 YL) 1,2,3,4 TETRAHYDROQUINOXALINE; 2 (4 METHOXYPHENYL) 3 (6 OXO 1,6 DIHYDROPYRIDAZIN 3 YL)QUINOXALINE; 2 PHENYL 3 (6 OXO 1,6 DIHYDROPYRIDAZIN 3 YL) 1,2,3,4 TETRAHYDROQUINOXALINE; 2 PHENYL 3 (6 OXO 1,6 DIHYDROPYRIDAZIN 3 YL)QUINOXALINE; CARRAGEENAN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; PYRIDAZINONE DERIVATIVE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IN VIVO STUDY; MALE; MOLECULAR DOCKING; NONHUMAN; PAW EDEMA; RAT; SINGLE DRUG DOSE;

EID: 77956482776     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00044-009-9218-4     Document Type: Article

References (29)

1. Abouzid K, Bekhit SA (2008) Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity. Bioorg Med Chem 16:5547-5556. doi:10.1016/j.bmc.2008.04.007
2. Abramson SB, Greenberg JD (2008) Are NSAIDs and selective cyclo-oxygenase 2 inhibitors associated with increased risk of myocardial infarction? Nat Clin Pract Rheumatol 4:182-183. doi:10.1038/ ncprheum0763
3. Arber N (2008) Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Cancer Epidemiol Biomarkers Prev 17:1852-1857. doi:10.1158/1055-9965.EPI-08-0167
4. Baddar FG, Nosseir MH, Doss NL, Messiha NN (1972) Pyridazines. Part 1 V. Action of Grignard reagents on 6-methyl- and 4,5- dihydro-6-a-styryl-pyridazin- 3(2H)-ones. J Chem Soc Perkin Trans 1:1091-1094. doi:10.1039/p19720001091
5. Beswick P, Bingham S, Bountra C, Brown T, Browning K, Campbell I, Chessell I, Clayton N, Collins S, Corfield J, Guntrip S, Haslam C, Lambeth P, Lucas F, Mathews N, Murkit G, Naylor A, Pegg N, Pickup E, Player H, Price H, Stevens A, Stratton S, Wiseman J (2004) Identification of 2,3-diarylpyrazolo[ 1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 14:5445-5448. doi:10.1016/j.bmcl.2004.07.089
6. Chen Q, Praveen Rao PN, Knaus EE (2005) Design, synthesis, and biological evaluation of N-acetyl-2- carboxybenzenesulfonamides: A novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem 13:2459-2468. doi:10.1016/j.bmc.2005.01.039
7. Chintakunta VK, Akella V, Vedula MS, Mamnoor PK, Mishra P, Casturi SR, Vangoori A, Rajagopalan R (2002) 3-O-Substituted benzyl pyridazinone derivatives as COX inhibitors. Eur J Med Chem 37:339-347. doi:10.1016/S0223-5234(02)01336-3
8. Coudert P, Couquelet J, Tronche P (1988) A New synthetic route to 4,6-diarylpyridazinones and some of their derivatives. J Heterocycl chem 25:799-802
9. DiRosa M, Willoughby DA (1971) Screens for anti-inflammatory drugs. J Pharm Pharmacol 23:297-300
10. Flower RJ (2003) The development of COX2 inhibitors. Nat Rev Drug Discov 2:179-191. doi: 10.1038/nrd1034
11. Garg R, Kurup A, Mekapati SB, Hansch C (2003) Cyclooxygenase (COX) inhibitors: a comparative QSAR study. Chem Rev 103:703-732. doi:10.1021/ cr020464a
12. Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koboldt CM, Seibert K (1996) A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem 271:15810-15814. doi:10.1074/jbc.271.26.15810
13. Jankowski J, Hunt R (2008) Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint. Cancer Epidemiol Biomarkers Prev 17:1858-1861. doi:10.1158/1055-9965.EPI-07-0710
14. Joo YH, Kim JK, Kang S-H, Noh M-S, Ha J-Y, Choi JK, Lim KM, Lee CH, Chung S (2003) 2,3- Diarylbenzopyran derivatives as a novel class of selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 13:413-417. doi:10.1016/S0960-894X(02)00952-6
15. Kalgutkar AS, Zhao Z (2001) Discovery and design of selective cyclooxygenase-2 inhibitors as nonulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents. Curr Drug Targets 2:79-106. doi:10.2174/1389450013348830
16. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC (1996) Structural basis for selective inhibition of cyclooxygenase-2 anti-inflammatory agents. Nature 384:644-648. doi:10.1038/3846 44a0
17. Li M, Wu X, Xu X (2001) Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway in esophageal cancer cells. Int J Cancer 93:218-223. doi:10.1002/ ijc.1322
18. Li CS, Brideau C, Chan CC, Savoie C, Claveau D, Gordon CR, Greig G, Gauthier JY, Lau CK, Riendeau D, Therien M, Wong E, Prasit P (2003) Pyridazinones as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 13:597-600. doi:10.1016/S0960-894X(02)01045-4
19. McKellar G, Madhok R, Singh G (2008) Update on the use of analgesics versus nonsteroidal antiinflammatory drugs in rheumatic disorders: risks and benefits. Curr Opin Rheumatol 20:239-245. doi:10.1097/BOR.0b013e3282fb03ec
20. Ranatunge RR, Garvey DS, Janero DR, Letts LG, Martino AM, Murty MG, Richardson SK, Young DY, Zemetseva IS (2004) Synthesis and selective cyclooxygenase-2 (COX-2) inhibitory activity of a series of novel bicyclic pyrazoles. Bioorg Med Chem 12:1357-1366. doi:10.1016/j.bmc.2004.01. 012
21. Reddy LR, Corey EJ (2005) Facile air oxidation of the conjugate base of rofecoxib (Vioxx™), a possible contributor to chronic human toxicity. Tetrahedron Lett 46:927-929. doi:10.1016/j.tetlet.2004. 12.055
22. Sinicrope FA, Gill S (2004) Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 23:63-75. doi:10.1023/A:1025863029529
23. Sircar I, Steffen RP, Bobowski G, Burke SE, Newton RS, Weishaar RE, Bristol JA, Evans DB (1989) Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4- (1H-imidazol-1-yl)phenyl] ethenyl]-3(2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure. J Med Chem 32:342-350. doi:10.1021/jm00122a011
24. Slater EA, Wierzbicki A, Sperl G, Thompson WJ (2001) Molecular modeling study of COX-2 inhibition by diarylheterocycles and sulindac sulfide. J Mol Struct 549:111-121
25. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ (1999) Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59:987-990
26. Uddin J, Rao P, McDonald R, Knaus EE (2004) A new class of acyclic 2-alkyl-1, 1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors. J Med Chem 47:6108-6111. doi:10.1021/jm049523y
27. Whitehead AJ, Ward RA, Jones MF (2007) Efficient synthesis of the selective COX-2 inhibitor GW406381X. Tetrahedron Lett 48:911-913. doi:10.1016/j.tetlet.2006.12.045
28. Yamac D, Ayyildiz T, Coskun U, Akyurek N, Dursun A, Seckin S, Koybasioglu F (2008). Pathol Res Pract 204:527-536. doi:10.1016/j.prp.2008.01.002
29. Zaheer SH, Kacker IK, Rao NS (1956) About the condensation of levulenic acid with aromatic aldehydes. Chem Ber 89:351-354. doi:10.1002/cber.19560890226